This inventor holds 3 USPTO granted patents. Top assignees: Yuhan Corporation, Janssen Biotech, Inc.. Active years: 2016-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Seongnam-si, KR (2016)
- Yongin-si, KR (2024)
Company Filing History:
3 out of 97 
2 out of 435 
Years Active: 2016-2025
Title: The Innovative Mind of Gyu Jin Lee: Pioneering Advances in EGFR Inhibition
Introduction: Gyu Jin Lee, an accomplished inventor based in Yongin-si, South Korea, has made significant contributions to the field of medicinal chemistry. With a focus on developing compounds that target mutated forms of the Epidermal Growth Factor Receptor (EGFR), Lee's work paves the way for promising therapeutic options in oncology.
Latest Patents: Gyu Jin Lee holds three patents, showcasing his innovative edge within the pharmaceutical industry. His latest inventions include:
1. **5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors** - This patent provides novel 5-membered heteroaryl-containing aminopyridine compounds and their pharmaceutically acceptable compositions, which demonstrate effective inhibition of certain mutated forms of EGFR.
2. **Substituted aminopyridine compounds as EGFR inhibitors** - This invention introduces aminopyridine compounds and their pharmaceutically acceptable compositions, also aimed at inhibiting particular mutated forms of EGFR, further emphasizing Lee's dedication to cancer research.
Career Highlights: Gyu Jin Lee has had a notable career marked by his tenure at esteemed organizations such as Yuhan Corporation and Janssen Biotech, Inc. His experiences in these renowned companies have undoubtedly been instrumental in shaping his innovative approach and understanding of the pharmaceutical landscape.
Collaborations: Throughout his career, Gyu Jin Lee has collaborated with talented professionals, including Kwan Hoon Hyun and Tae Kyun Kim. These partnerships highlight the collaborative spirit in research and development, enhancing the potential for impactful results in their projects.
Conclusion: Gyu Jin Lee stands out as a leading inventor in the field of EGFR inhibition. With his impressive track record of patents and collaborations, he continues to drive innovation forward, contributing immensely to the fight against cancer and the advancement of therapeutic techniques.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile